Financial Architects, Inc Merus N.V. Transaction History

Financial Architects, Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 14, 2019	SELL	$12.93 - $16.83 $1,293 - $1,682	-100 Closed	0 $0
Q1 2019 May 13, 2019	BUY	$11.09 - $15.83 $1,109 - $1,583	100 New	100 $1,000
Q1 2019 May 03, 2019	SELL	$11.09 - $15.83 $1,109 - $1,583	-100 Closed	0 $0
Q1 2018 Apr 23, 2018	BUY	$16.07 - $19.87 $1,607 - $1,987	100 New	100 $2,000
Q4 2017 Feb 12, 2018	SELL	$14.23 - $21.28 $1,423 - $2,128	-100 Closed	0 $0
Q3 2017 Nov 01, 2017	BUY	$13.6 - $19.87 $1,360 - $1,987	100	100 $2,000

200

61.9M

243K

300K

Ticker MRUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,878,200
Market Cap $2.08B
Description
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...

Get notified when there are updates to the investment portfolio of Financial Architects, Inc, based on Form 13F filings with the SEC.

Stay updated on Financial Architects, Inc with notifications on news.